Status:
COMPLETED
Efficacy of Chinese Herbal Medicine to Prevent and Treat COVID-19 Close Contacts
Lead Sponsor:
Hong Kong Baptist University
Conditions:
Healthy Participants
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
This is a randomized, blank-controlled study in adults with household contact exposure to individuals with SARS-CoV-2 infection. All subjects in the study will be household contacts with close exposur...
Eligibility Criteria
Inclusion
- Household contact exposure to individuals with SARS-CoV-2 infection
- Aged ≥18
- General healthy or have a chronic, stable medical condition
- Voluntarily signing a written informed consent form
- Able to follow written and oral instructions in Chinese
Exclusion
- Moderate to severe symptomatic SARS-CoV-2 infection
- An allergic history to Chinese herbal drugs or a known allergy to the ingredients of the study drug
- Pregnancy, breastfeeding or plan to become pregnant within the study timeframe
- Vulnerable adults (i.e., mentally or physically disabled to take care of himself/herself)
- Any physical examination findings, and/or history of any illness, or concomitant medications that, in the opinion of the study investigator, might not be suitable to participate in the study
Key Trial Info
Start Date :
March 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 22 2022
Estimated Enrollment :
2163 Patients enrolled
Trial Details
Trial ID
NCT05269511
Start Date
March 14 2022
End Date
June 22 2022
Last Update
April 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
School of Chinese Medicine, Hong Kong Baptist University
Hong Kong, Hong Kong, China